Quest Diagnostics posts Q4 revenue and earnings beat, raises dividend

Published 30/01/2025, 12:53
Updated 30/01/2025, 13:51
Quest Diagnostics posts Q4 revenue and earnings beat, raises dividend

NEW YORK - Quest Diagnostics (NYSE:DGX) reported fourth quarter earnings and revenue that exceeded analyst expectations, while also announcing a dividend increase. However, shares edged lower in early trading.

The diagnostic testing company posted adjusted earnings per share of $2.23, beating the consensus estimate of $2.19. Revenue came in at $2.62 billion, surpassing expectations of $2.58 billion and representing a 14.5% increase YoY.

Quest Diagnostics saw robust 14.5% revenue growth in Q4, including approximately 5% organic growth. The company completed eight acquisitions in 2024, including LifeLabs in Canada, which helped drive results.

"Our guidance for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024," said Jim Davis, Chairman, CEO and President.

For full year 2025, Quest expects revenue between $10.70 billion and $10.85 billion, representing 8.4% to 9.9% growth. Adjusted EPS is forecast at $9.55 to $9.80.

The company also announced a 6.7% increase in its quarterly dividend to $0.80 per share.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.